{"schema_version":"secwatch.filing_event.v1","accession":"0001193805-23-001384","form_type":"8-K","ticker":"IMUX","cik":"0001280776","company_name":"IMMUNIC, INC.","filed_at":"2023-10-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.516367+00:00","generated_at":"2026-06-10T02:03:45.549694+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Immunic reports positive Phase 2 CALLIPER interim data: NfL reduced 22.4% vs placebo in PMS","bullets":["Vidofludimus calcium lowered serum NfL by 22.4% vs placebo at 24 weeks in overall PMS (p=0.01 post hoc).","Non-active SPMS subgroup showed 20.1% NfL reduction; PPMS showed 18.8% reduction.","GFAP increased 3.7% for drug vs 4.4% for placebo at 24 weeks; 2.7% vs 6.4% at 48 weeks.","Top-line CALLIPER data expected April 2025; Phase 3 ENSURE interim data late 2024.","NfL reduction numerically higher than historical Ocrevus data in PPMS (22.4% vs 12.4%)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-23-001384","json":"https://secwatch.observer/filing/0001193805-23-001384.json","markdown":"https://secwatch.observer/filing/0001193805-23-001384.md","text":"https://secwatch.observer/filing/0001193805-23-001384.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1280776/000119380523001384/0001193805-23-001384-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1280776/000119380523001384/e618990_8k-immunic.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T02:03:45.549694+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}